Berry Announces Strong Fourth Quarter and Fiscal Year 2023 Results
Fourth Quarter Highlights
-
GAAP: Net sales of
$3.1 billion ; Operating income of$301 million ; Earnings per share (EPS) of$1.55 -
Non-GAAP: Operating EBITDA of
$547 million ; Adjusted EPS of$2.28 -
Returned
$216 million to shareholders ($185 million via share repurchases and$31 million in dividends)
Fiscal Year Highlights
-
GAAP: Net sales of
$12.7 billion ; Operating income of$1.1 billion ; EPS of$4.95 -
Non-GAAP: Operating EBITDA of
$2.05 billion ; Adjusted EPS of$7.42 -
Cash flow from operations of
$1.6 billion ; Free cash flow of$926 million -
Returned
$728 million to shareholders ($601 million via share repurchases and$127 million in dividends)
Fiscal Year 2024 Outlook
-
Adjusted EPS range of
$7.35 -$7.85 per share -
Cash flow from operations range of
$1.35 -$1.45 billion ; Free cash flow range of$800 -$900 million -
Announced a 10% increase to the quarterly dividend to
$0.275 per share - Committed to debt reduction along with returning capital to shareholders through share repurchases and dividends
In line with our commitment to drive long-term shareholder value, we expect to use our cash in fiscal 2024 to reduce our debt, repurchase shares opportunistically, and pay our recently increased dividend. Looking ahead, we are optimistic about our future and expect a more normal operating environment in fiscal 2024. We believe that, both the easing of inflationary pressures on consumers and the increase of promotional activity by our customers will lead to demand improvement as the year progresses.”
Key Financials (1) |
|||||||||||||
|
|
Fiscal Year |
|||||||||||
GAAP results |
2023 |
2022 |
2023 |
2022 |
|||||||||
Net sales |
|
$ |
3,087 |
|
$ |
3,421 |
|
$ |
12,664 |
|
$ |
14,495 |
|
Operating income |
|
|
301 |
|
336 |
|
1,079 |
|
1,242 |
||||
EPS (diluted) |
|
|
1.55 |
|
|
1.85 |
|
|
4.95 |
|
|
5.77 |
|
|
|
Reported |
Comparable |
Fiscal Year |
Reported |
Comparable |
||||||||||
Adjusted non-GAAP results |
2023 |
2022 |
% |
% |
2023 |
2022 |
% |
% |
||||||||
Net sales |
$ |
3,087 |
|
$ |
3,421 |
|
(10%) |
(12%) |
$ |
12,664 |
|
$ |
14,495 |
|
(13%) |
(12%) |
Operating EBITDA |
|
547 |
|
539 |
1% |
flat |
|
2,053 |
|
2,101 |
(2%) |
flat |
||||
Adjusted EPS (diluted) |
|
2.28 |
|
|
2.19 |
|
4% |
1% |
|
7.42 |
|
|
7.40 |
|
flat |
1% |
(1) |
Adjusted non-GAAP results exclude items not considered to be ongoing operations. In addition, comparable change % excludes the impacts of foreign currency, acquisitions, and recent divestitures. Further details related to non-GAAP measures and reconciliations can be found under our “Non-GAAP Financial Measures and Estimates” section or in reconciliation tables in this release. In millions of USD, except per share data |
Financial Results – Fourth Quarter 2023
Consolidated Overview
The net sales decline is primarily attributed to decreased selling prices of
The operating income decrease is primarily attributed to a
Net sales were essentially flat primarily attributed to a 3% volume decline due to softer consumer and industrial market demand in
The operating income decrease is primarily attributed to a
The net sales decline is primarily attributed to decreased selling prices of
The operating income decrease is primarily attributed to a
Health, Hygiene, & Specialties
The net sales decline is primarily attributed to decreased selling prices of
The operating income decrease is primarily attributed to an unfavorable impact from the volume decline partially offset by a favorable impact from price cost spread.
During the fourth quarter, we announced that we have initiated a formal process to evaluate strategic alternatives for our Health, Hygiene and Specialties segment to provide ways to drive long-term value to shareholders, which includes continuously evaluating our portfolio to ensure the Company is best positioned to execute our strategic objectives. We remain a trusted supplier and partner to our customers and colleagues of this segment. There is no certainty on any formal decision, nor definitive timetable, for this process. If and when appropriate, a further announcement will be made.
Engineered Materials
The net sales decline is primarily attributed to decreased selling prices of
The operating income decrease is primarily attributed to an unfavorable impact from the volume decline, partially offset by a favorable impact from price cost spread and improved mix.
Financial Results – Fiscal Year 2023
Consolidated Overview
The net sales decline is primarily attributed to decreased selling prices of
The operating income decrease is primarily attributed to a
The net sales decline is primarily attributed to a 5% volume decline, fiscal 2022 divestiture sales of
The operating income decrease is primarily attributed to a
The net sales decline is primarily attributed to decreased selling prices of
The operating income increase is primarily attributed to a
Health, Hygiene, & Specialties
The net sales decline is primarily attributed to decreased selling prices of
The operating income decrease is primarily attributed to a
Engineered Materials
The net sales decline is primarily attributed to decreased selling prices of
The operating income increase is primarily attributed to an
Cash Returns to Shareholders
Berry generates significant cash flow and is committed to returning capital to shareholders. This annual cash flow provides substantial capacity to simultaneously reinvest in the business for organic growth, pursue bolt-on acquisitions, pay down debt and return cash to shareholders through a compelling dividend as well as share repurchases. The Company expects to be within its leverage target of 2.5x – 3.5x by the end of fiscal 2024, while also returning cash to shareholders during the year, through continued share repurchases and dividends, subject to market conditions, available cash on hand and cash needs, overall financial condition, and other factors considered relevant by our Board of Directors.
Dividend and Share Repurchases
As previously announced, Berry’s Board of Directors increased the quarterly cash dividend by 10% to
Fiscal Year 2024 Guidance
(based on information available as of
-
Adjusted earnings per share range of
$7.35 -$7.85 -
Cash flow from operations range of
$1.35-$1.45 billion ; free cash flow range of$800-900 million - Committed to debt reduction along with returning capital to shareholders through share repurchases and dividends
Investor Conference Call
The Company will host a conference call today,
By Telephone
Participants may register for the call here now or any time up to and during the time of the call, and will immediately receive the dial-in number and a unique pin to access the call. While you may register at any time up to and during the time of the call, you are encouraged to join the call 10 minutes prior to the start of the event.
Via the Internet
The conference call and accompanying webcast slides will also be broadcast live over the internet. To access the event, click on the following link: https://ir.berryglobal.com/financials. A replay of the webcast will be available via the same link on our website approximately two hours after the completion of the call.
About Berry
At
Non-GAAP Financial Measures and Estimates
This press release includes non-GAAP financial measures such as operating EBITDA, Adjusted operating income, Adjusted earnings per share (or adjusted EPS), free cash flow, and comparable basis net sales, comparable adjusted EPS and comparable operating EBITDA. A reconciliation of these non-GAAP financial measures to comparable measures determined in accordance with accounting principles generally accepted in
Forward Looking Statements
Statements in this release that are not historical, including statements relating to the expected future performance of the Company, are considered “forward looking” within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “would,” “could,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” “projects,” “outlook,” “anticipates” or “looking forward,” or similar expressions that relate to our strategy, plans, intentions, or expectations. All statements we make relating to our estimated and projected earnings, margins, costs, expenditures, cash flows, growth rates, and financial results or to our expectations regarding future industry trends are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments.
Our actual results may differ materially from those that we expected due to a variety of factors, including without limitation: (1) risks associated with our substantial indebtedness and debt service; (2) changes in prices and availability of resin and other raw materials and our ability to pass on changes in raw material prices to our customers on a timely basis; (3) risks related to acquisitions or divestitures and integration of acquired businesses and their operations, and realization of anticipated cost savings and synergies; (4) risks related to international business, including transactional and translational foreign currency exchange rate risk and the risks of compliance with applicable export controls, sanctions, anti-corruption laws and regulations; (5) increases in the cost of compliance with laws and regulations, including environmental, safety, and climate change laws and regulations; (6) labor issues, including the potential labor shortages, shutdowns or strikes, or the failure to renew effective bargaining agreements; (7) risks related to disruptions in the overall global economy, persistent inflation, supply chain disruptions, and the financial markets that may adversely impact our business; (8) risk of catastrophic loss of one of our key manufacturing facilities, natural disasters, and other unplanned business interruptions; (9) risks related to weather-related events and longer-term climate change patterns; (10) risks related to the failure of, inadequacy of, or attacks on our information technology systems and infrastructure; (11) risks that our restructuring programs may entail greater implementation costs or result in lower cost savings than anticipated; (12) risks related to future write-offs of substantial goodwill; (13) risks of competition, including foreign competition, in our existing and future markets; (14) risks related to market conditions associated with our share repurchase program; (15) risks related to market disruptions and increased market volatility; and (16) the other factors and uncertainties discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K and subsequent filings with the
|
|||||||||||||||
Consolidated Statements of Income (Unaudited) |
|||||||||||||||
|
Quarterly Period Ended |
|
Fiscal Year Ended |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
||||||||
Net sales |
$ |
3,087 |
|
|
$ |
3,421 |
|
|
$ |
12,664 |
|
|
$ |
14,495 |
|
Costs and expenses: |
|
|
|
|
|
|
|
||||||||
Cost of goods sold |
|
2,481 |
|
|
|
2,834 |
|
|
|
10,354 |
|
|
|
12,123 |
|
Selling, general and administrative |
|
215 |
|
|
|
185 |
|
|
|
886 |
|
|
|
850 |
|
Amortization of intangibles |
|
62 |
|
|
|
61 |
|
|
|
243 |
|
|
|
257 |
|
Restructuring and transaction activities |
|
28 |
|
|
|
5 |
|
|
|
102 |
|
|
|
23 |
|
Operating income |
|
301 |
|
|
|
336 |
|
|
|
1,079 |
|
|
|
1,242 |
|
Other expense |
|
18 |
|
|
|
9 |
|
|
|
31 |
|
|
|
22 |
|
Interest expense, net |
|
78 |
|
|
74 |
|
|
306 |
|
|
286 |
||||
Income before income taxes |
|
205 |
|
|
|
253 |
|
|
|
742 |
|
|
|
934 |
|
Income tax expense |
|
19 |
|
|
|
20 |
|
|
|
133 |
|
|
|
168 |
|
Net income |
$ |
186 |
|
|
$ |
233 |
|
|
$ |
609 |
|
|
$ |
766 |
|
|
|
|
|
|
|
|
|
||||||||
Basic net income per share |
$ |
1.59 |
|
|
$ |
1.87 |
|
|
$ |
5.07 |
|
|
$ |
5.87 |
|
Diluted net income per share |
|
1.55 |
|
|
|
1.85 |
|
|
|
4.95 |
|
|
|
5.77 |
|
|
|
|
|
|
|
|
|
||||||||
Outstanding weighted average shares (in millions) |
|
|
|
|
|
|
|
||||||||
Basic |
|
117.3 |
|
|
|
124.7 |
|
|
|
120.1 |
|
|
|
130.6 |
|
Diluted |
|
120.2 |
|
|
|
126.0 |
|
|
|
123.0 |
|
|
|
132.8 |
|
|
|
|
|
|
|
|
|
Condensed Consolidated Balance Sheets (Unaudited) |
||||||
(in millions of USD) |
|
|
||||
Cash and cash equivalents |
$ |
1,203 |
|
$ |
1,410 |
|
Accounts receivable |
|
1,568 |
|
|
1,777 |
|
Inventories |
|
1,557 |
|
|
1,802 |
|
Other current assets |
|
205 |
|
|
175 |
|
Property, plant, and equipment |
|
4,576 |
|
4,342 |
||
|
|
7,478 |
|
|
7,450 |
|
Total assets |
$ |
16,587 |
|
$ |
16,956 |
|
Current liabilities, excluding current debt |
|
2,703 |
|
|
2,831 |
|
Current and long-term debt |
|
8,980 |
|
|
9,255 |
|
Other long-term liabilities |
|
1,688 |
|
|
1,674 |
|
Stockholders’ equity |
|
3,216 |
|
|
3,196 |
|
Total liabilities and stockholders' equity |
$ |
16,587 |
|
$ |
16,956 |
|
|
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||||||
|
Fiscal Year Ended |
||||||
(in millions of USD) |
|
|
|
||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
609 |
|
|
$ |
766 |
|
Depreciation |
|
575 |
|
|
|
562 |
|
Amortization of intangibles |
|
243 |
|
|
|
257 |
|
Non-cash interest, net |
|
(61 |
) |
|
|
6 |
|
Settlement of derivatives |
|
36 |
|
|
|
201 |
|
Deferred income tax |
|
(117 |
) |
|
|
(48 |
) |
Share-based compensation expense |
|
42 |
|
|
|
39 |
|
Other non-cash operating activities, net |
|
22 |
|
|
|
(22 |
) |
Changes in working capital |
|
266 |
|
|
|
(198 |
) |
Net cash from operating activities |
|
1,615 |
|
|
|
1,563 |
|
|
|
|
|
||||
Cash flows from investing activities: |
|
|
|
||||
Additions to property, plant, and equipment, net |
|
(689 |
) |
|
|
(687 |
) |
Settlement of net investment hedges |
|
- |
|
|
|
76 |
|
Divestiture (acquisition) of businesses and other |
|
(87 |
) |
|
|
128 |
|
Net cash from investing activities |
|
(776 |
) |
|
|
(483 |
) |
|
|
|
|
||||
Cash flows from financing activities: |
|
|
|
||||
Repayments on long-term borrowings |
|
(869 |
) |
|
|
(22 |
) |
Proceeds from long-term borrowings |
|
496 |
|
|
|
- |
|
Repurchase of common stock |
|
(601 |
) |
|
|
(709 |
) |
Proceeds from issuance of common stock |
|
36 |
|
|
|
27 |
|
Dividends paid |
|
(127 |
) |
|
|
- |
|
Other, net |
|
(6 |
) |
|
|
- |
|
Net cash from financing activities |
|
(1,071 |
) |
|
|
(704 |
) |
Effect of currency translation on cash |
|
25 |
|
|
|
(57 |
) |
Net change in cash and cash equivalents |
|
(207 |
) |
|
|
319 |
|
Cash and cash equivalents at beginning of period |
|
1,410 |
|
|
|
1,091 |
|
Cash and cash equivalents at end of period |
$ |
1,203 |
|
|
$ |
1,410 |
|
|
|
|
|
||||
|
|
|
|
||||
Non- |
|
|
|
||||
Cash flow from operating activities |
$ |
1,615 |
|
|
$ |
1,563 |
|
Additions to property, plant, and equipment (net) |
|
(689 |
) |
|
|
(687 |
) |
Non- |
$ |
926 |
|
|
$ |
876 |
|
Segment and Supplemental Comparable Basis Information (Unaudited) |
|||||||||||||||||||
|
Quarterly Period Ended |
||||||||||||||||||
(in millions of USD) |
Consumer
|
|
Consumer
|
|
Health,
|
|
Engineered
|
|
Total |
||||||||||
Net sales |
$ |
1,000 |
|
|
$ |
786 |
|
|
$ |
630 |
|
|
$ |
671 |
|
|
$ |
3,087 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating income |
$ |
84 |
|
|
$ |
94 |
|
|
$ |
36 |
|
|
$ |
87 |
|
|
$ |
301 |
|
Depreciation and amortization |
|
80 |
|
|
|
58 |
|
|
|
45 |
|
|
|
29 |
|
|
|
212 |
|
Restructuring and transaction activities |
|
18 |
|
|
|
7 |
|
|
|
2 |
|
|
|
1 |
|
|
|
28 |
|
Other non-cash charges (1) |
|
2 |
|
|
2 |
|
|
1 |
|
|
1 |
|
|
6 |
|||||
Operating EBITDA |
$ |
184 |
|
|
$ |
161 |
|
|
$ |
84 |
|
|
$ |
118 |
|
|
$ |
547 |
|
|
|
|
|
|
|
|
|
|
|
|
Quarterly Period Ended |
||||||||||||||||||
Reported net sales |
$ |
1,003 |
|
|
$ |
888 |
|
$ |
738 |
|
|
$ |
792 |
|
$ |
3,421 |
|
||
Foreign currency and divestitures |
|
56 |
|
|
|
13 |
|
|
25 |
|
|
|
9 |
|
|
103 |
|
||
Comparable net sales (2) |
$ |
1,059 |
|
|
$ |
901 |
|
$ |
763 |
|
|
$ |
801 |
|
$ |
3,524 |
|
||
Operating income |
$ |
98 |
|
|
$ |
103 |
|
$ |
44 |
|
|
$ |
91 |
|
$ |
336 |
|
||
Depreciation and amortization |
|
75 |
|
|
|
53 |
|
|
43 |
|
|
|
28 |
|
|
199 |
|
||
Restructuring and transaction activities |
|
— |
|
|
|
2 |
|
|
3 |
|
|
|
— |
|
|
5 |
|
||
Other non-cash charges (1) |
|
(1 |
) |
|
|
— |
|
|
— |
|
|
|
— |
|
|
(1 |
) |
||
Foreign currency and divestitures |
|
7 |
|
|
|
4 |
|
(5 |
) |
|
|
1 |
|
7 |
|
||||
Comparable operating EBITDA (2) |
$ |
179 |
|
|
$ |
162 |
|
$ |
85 |
|
|
$ |
120 |
|
$ |
546 |
|
||
|
|
|
|
|
|
|
|
(1) |
Other non-cash charges are primarily stock compensation expense |
(2) |
The prior year comparable basis change excludes the impacts of foreign currency, acquisitions, and divestitures. Further details related to non-GAAP measures and reconciliations can be found under our “Non-GAAP Financial Measures and Estimates” section or in reconciliation tables in this release. |
|
Fiscal Year Ended |
||||||||||||||||||
(in millions of USD) |
Consumer
|
|
Consumer
|
|
Health,
|
|
Engineered
|
|
Total |
||||||||||
Net sales |
$ |
4,031 |
|
|
$ |
3,122 |
|
|
$ |
2,627 |
|
|
$ |
2,884 |
|
|
$ |
12,664 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating income |
$ |
273 |
|
|
$ |
346 |
|
|
$ |
127 |
|
|
$ |
333 |
|
|
$ |
1,079 |
|
Depreciation and amortization |
|
310 |
|
|
|
217 |
|
|
|
177 |
|
|
|
114 |
|
|
|
818 |
|
Restructuring and transaction activities |
|
50 |
|
|
|
23 |
|
|
|
22 |
|
|
|
7 |
|
|
|
102 |
|
Other non-cash charges (1) |
25 |
|
|
12 |
|
|
8 |
|
|
9 |
|
|
54 |
||||||
Operating EBITDA |
$ |
658 |
|
|
$ |
598 |
|
|
$ |
334 |
|
|
$ |
463 |
|
|
$ |
2,053 |
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended |
||||||||||||||||||
Reported net sales |
$ |
4,293 |
|
|
$ |
3,548 |
|
|
$ |
3,166 |
|
|
$ |
3,488 |
|
|
$ |
14,495 |
|
Foreign currency and divestitures |
|
(167 |
) |
|
|
26 |
|
|
|
7 |
|
|
|
(31 |
) |
|
|
(165 |
) |
Comparable net sales (2) |
$ |
4,126 |
|
|
$ |
3,574 |
|
|
$ |
3,173 |
|
|
$ |
3,457 |
|
|
$ |
14,330 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating income |
$ |
346 |
|
|
$ |
338 |
|
|
$ |
230 |
|
|
$ |
328 |
|
|
$ |
1,242 |
|
Depreciation and amortization |
|
317 |
|
|
|
214 |
|
|
|
176 |
|
|
|
112 |
|
|
|
819 |
|
Restructuring and transaction activities |
|
10 |
|
|
|
5 |
|
|
|
6 |
|
|
|
2 |
|
|
|
23 |
|
Other non-cash charges (1) |
|
(5 |
) |
|
|
8 |
|
|
|
8 |
|
|
|
6 |
|
|
|
17 |
|
Foreign currency and divestitures |
|
(31 |
) |
|
|
9 |
|
|
(13 |
) |
|
|
(3 |
) |
|
|
(38 |
) |
|
Comparable operating EBITDA (2) |
$ |
638 |
|
|
$ |
574 |
|
|
$ |
407 |
|
|
$ |
445 |
|
|
$ |
2,064 |
|
|
|
|
|
|
|
|
|
|
|
(1) |
Other non-cash charges are primarily stock compensation expense |
(2) |
The prior year comparable basis change excludes the impacts of foreign currency, acquisitions, and divestitures. Further details related to non-GAAP measures and reconciliations can be found under our “Non-GAAP Financial Measures and Estimates” section or in reconciliation tables in this release. |
Reconciliation of Non-GAAP Measures |
|||||||||||||||
|
|||||||||||||||
Reconciliation of Net income and earnings per share (EPS) to adjusted operating income, operating earnings before interest, tax, depreciation and amortization (EBITDA), and adjusted EPS |
|||||||||||||||
(in millions of USD, except per share data amounts) |
|||||||||||||||
|
Quarterly Period Ended |
Fiscal Year Ended |
|||||||||||||
|
|
|
|
|
|
|
|
||||||||
Net income |
$ |
186 |
|
|
$ |
233 |
|
|
$ |
609 |
|
|
$ |
766 |
|
Add: other expense |
|
18 |
|
|
|
9 |
|
|
|
31 |
|
|
|
22 |
|
Add: interest expense |
|
78 |
|
|
|
74 |
|
|
|
306 |
|
|
|
286 |
|
Add: income tax expense |
|
19 |
|
|
20 |
|
|
133 |
|
|
168 |
||||
Operating income |
$ |
301 |
|
|
$ |
336 |
|
|
$ |
1,079 |
|
|
$ |
1,242 |
|
|
|
|
|
|
|
|
|
||||||||
Add: restructuring and transaction activities |
|
28 |
|
|
|
5 |
|
|
|
102 |
|
|
|
23 |
|
Add: other non-cash charges (1) |
|
6 |
|
|
|
(1 |
) |
|
|
54 |
|
|
|
17 |
|
Adjusted operating income (4) |
$ |
335 |
|
|
$ |
340 |
|
|
$ |
1,235 |
|
|
$ |
1,282 |
|
|
|
|
|
|
|
|
|
||||||||
Add: depreciation |
|
150 |
|
|
|
138 |
|
|
|
575 |
|
|
|
562 |
|
Add: amortization of intangibles |
|
62 |
|
|
|
61 |
|
|
|
243 |
|
|
|
257 |
|
Operating EBITDA (4) |
$ |
547 |
|
|
$ |
539 |
|
|
$ |
2,053 |
|
|
$ |
2,101 |
|
|
|
|
|
|
|
|
|
Net income per diluted share |
$ |
1.55 |
|
|
$ |
1.85 |
|
|
$ |
4.95 |
|
|
$ |
5.77 |
|
Other expense, net |
|
0.15 |
|
|
|
0.07 |
|
|
|
0.25 |
|
|
|
0.17 |
|
Restructuring and transaction activities |
|
0.23 |
|
|
|
0.04 |
|
|
|
0.83 |
|
|
|
0.17 |
|
Amortization of intangibles from acquisitions (2) |
|
0.52 |
|
|
|
0.48 |
|
|
|
1.98 |
|
|
|
1.94 |
|
Non-comparable tax items (3) |
|
— |
|
|
|
(0.14 |
) |
|
|
— |
|
|
|
(0.13 |
) |
Income tax impact on items above |
|
(0.17 |
) |
|
|
(0.14 |
) |
|
|
(0.59 |
) |
|
|
(0.52 |
) |
Foreign currency, acquisitions, and divestitures |
|
— |
|
|
|
0.06 |
|
|
|
— |
|
|
|
(0.06 |
) |
Adjusted net income per diluted share (4) |
$ |
2.28 |
|
|
$ |
2.25 |
|
|
$ |
7.42 |
|
|
$ |
7.34 |
|
|
|
|
|
|
|
|
|
Reconciliation of Cash flow from operating activities to Free cash flow |
|
(in millions of USD) |
|
|
Estimated
|
Cash flow from operating activities |
|
Net additions to property, plant, and equipment |
(550) |
Free cash flow (4) |
|
(1) |
Other non-cash charges are primarily stock compensation expense |
(2) |
Amortization of intangibles from acquisition are added back to better align our calculation of adjusted EPS with peers. |
(3) |
During the 2022 fiscal year, the Company obtained certain tax benefits of |
(4) |
Supplemental financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in |
We define “free cash flow” as cash flow from operating activities, less net additions to property, plant, and equipment. We believe free cash flow is useful to an investor in evaluating our liquidity because free cash flow and similar measures are widely used by investors, securities analysts, and other interested parties in our industry to measure a company’s liquidity. We also believe free cash flow is useful to an investor in evaluating our liquidity as it can assist in assessing a company’s ability to fund its growth through its generation of cash. |
|
We also use Adjusted operating EBITDA, Adjusted EPS and comparable basis measures, among other measures, to evaluate management performance and in determining performance-based compensation. Operating EBITDA is a measure widely used by investors, securities analysts, and other interested parties in our industry to measure a company’s performance. We also believe EBITDA and Adjusted operating income are useful to an investor in evaluating our performance without regard to revenue and expense recognition, which can vary depending upon accounting methods. |
|
(BERY-F) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116763663/en/
VP, Investor Relations
+1 (812) 306 2964
ir@berryglobal.com
Source: